Novel n-3 Immunoresolvents: Structures and Actions

Citations Over TimeTop 1% of 2013 papers

Abstract

Resolution of inflammation is now held to be an active process where autacoids promote homeostasis. Using functional-metabololipidomics and in vivo systems, herein we report that endogenous n-3 docosapentaenoic (DPA) acid is converted during inflammation-resolution in mice and by human leukocytes to novel n-3 products congenerous to D-series resolvins (Rv), protectins (PD) and maresins (MaR), termed specialized pro-resolving mediators (SPM). The new n-3 DPA structures include 7,8,17-trihydroxy-9,11,13,15E,19Z-docosapentaenoic acid (RvD1(n-3 DPA)), 7,14-dihydroxy-8,10,12,16Z,19Z-docosapentaenoic acid (MaR1(n-3 DPA)) and related bioactive products. Each n-3 DPA-SPM displayed protective actions from second organ injury and reduced systemic inflammation in ischemia-reperfusion. The n-3 DPA-SPM, including RvD1(n-3 DPA) and MaR1(n-3 DPA), each exerted potent leukocyte directed actions in vivo. With human leukocytes each n-3 DPA-SPM reduced neutrophil chemotaxis, adhesion and enhanced macrophage phagocytosis. Together, these findings demonstrate that n-3 DPA is converted to novel immunoresolvents with actions comparable to resolvins and are likely produced in humans when n-3 DPA is elevated.

Related Papers

• → Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases(2013)435 cited
• → Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation(2015)224 cited
• → Regulation of endothelium-derived vasoactive autacoid production by hemodynamic forces(2003)142 cited
• → Interdependence of lipoxin A ₄ and heme‐oxygenase in counter‐regulating inflammation during corneal wound healing(2007)89 cited
• → Selected Autacoids as Modulators of Lymphocyte Function(1988)5 cited